Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

被引：0
|
作者：
Naoko Imanishi
Kazue Yoneda
Akihiro Taira
Yoshinobu Ichiki
Naoko Sato
Masanori Hisaoka
Fumihiro Tanaka
机构：
[1] University of Occupational and Environmental Health Japan,Second Department of Surgery (Chest Surgery)
[2] University of Occupational and Environmental Health Japan,Department of Pathology, School of Medicine
[3] University of Occupational and Environmental Health Japan,Department of Pathology and Oncology, School of Medicine
来源：
Surgical Case Reports | / 4卷 / 1期
关键词：
ALK; Alectinib; Pathologic response; Adenocarcinoma; Lung;
D O I：
10.1186/s40792-018-0430-7
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
    Imanishi, Naoko
    Yoneda, Kazue
    Taira, Akihiro
    Ichiki, Yoshinobu
    Sato, Naoko
    Hisaoka, Masanori
    Tanaka, Fumihiro
    [J]. SURGICAL CASE REPORTS, 2018, 4
  • [2] Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung
    Balzer, Ben W. R.
    Loo, Christine
    Wegner, Eva A.
    Nath, Christa E.
    Lee, Samiuela
    Smith, Chantelle
    Lewis, Craig R.
    Trahair, Toby N.
    Anazodo, Antoinette C.
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2018, 35 (7-8) : 415 - 421
  • [3] ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
    Song, Lianxi
    Zeng, Liang
    Zhang, Yongchang
    [J]. THORACIC CANCER, 2022, 13 (07) : 1095 - 1097
  • [4] Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
    Shiihara, Jun
    Ohyanagi, Fumiyoshi
    Amari, Hikari
    Toda, Minemichi
    Tahara, Hiroki
    Yuzawa, Motoi
    Maeda, Yuki
    Nomura, Motoko
    Mizushina, Yoshiko
    Nagai, Yoshiaki
    Ohta, Hiromitsu
    Yamaguchi, Yasuhiro
    [J]. THORACIC CANCER, 2021, 12 (17) : 2420 - 2423
  • [5] A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib
    Lim, Chloe A.
    Banyi, Norbert
    Tucker, Tracy
    Ionescu, Diana N.
    Melosky, Barbara
    [J]. CURRENT ONCOLOGY, 2022, 29 (02) : 848 - 852
  • [6] SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
    Xia, G.
    Yu, S.
    Ni, J.
    Song, M.
    Zhang, J.
    Huang, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S526 - S527
  • [7] Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma
    Nakasuka, Takamasa
    Ichihara, Eiki
    Makimoto, Go
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) : E168 - E169
  • [8] Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
    Tanaka H.
    Taima K.
    Morimoto T.
    Nakamura K.
    Tanaka Y.
    Itoga M.
    Takanashi S.
    Okumura K.
    [J]. BMC Research Notes, 9 (1)
  • [9] Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma
    Mattar, Marissa S.
    Chang, Jason
    Benayed, Ryma
    Halpenny, Darragh
    Powers, Astin
    Kleiner, David E.
    Drilon, Alexander
    Kris, Mark G.
    [J]. CLINICAL LUNG CANCER, 2020, 21 (01) : E25 - E29
  • [10] Clinicophopathologic Features in ALK-Rearranged Lung Adenocarcinoma in the Korea
    Kim, Eun Kyoung
    Choi, Chang-Min
    Lee, Dae Ho
    Choi, Jene
    Jang, Se Jin
    Suh, Cheolwon
    Lee, Jung Shin
    Kim, Sang-We
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S404 - S405
12345